PROLONGED SURVIVAL IN ACUTE MYELOGENOUS LEUKAEMIA WITHOUT MAINTENANCE CHEMOTHERAPY

Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Jacob Zighelboim(University of California, Los Angeles), Robert Elashoff(Melanoma Institute Australia), Kenneth A. Foon(Markey Cancer Center), Andrew Jacobs(Virginia Mason Medical Center), RobertPeter Gale(University of California, Los Angeles), Ralph V. Boccia(Center for Cancer and Blood Disorders)

The Lancet

April 1, 1984

10.1016/s0140-6736(84)91350-3

Cited by 69

Related Papers

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

|Journal of Clinical Oncology|1997|1.3k

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

|Blood|1997|1.2k

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

|Journal of Clinical Oncology|1998|927

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

|Breast Cancer Research and Treatment|2017|761

Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

|Blood|2001|570